Evidence map›Paper›PMID 35047556›Full record

ArticleFrontiers in molecular biosciences2021

miR-3587 Inhibitor Attenuates Ferroptosis Following Renal Ischemia-Reperfusion Through HO-1.

Wenqiang Tao, Fen Liu, Jianguo Zhang, Shangmiao Fu, Hui Zhan, Kejian Qian

Open access · goldAbstract read
In one paragraph

Article in Frontiers in molecular biosciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 49 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Mechanisms of Protection Against Oxidative Stress During Hibernation.International journal of molecular sciences · 2026
    Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. The interplay of miRNAs and ferroptosis in diseases related to iron overload.Apoptosis : an international journal on programmed cell death · 2024
    Review
  15. Ferroptosis inhibitors: past, present and future.Frontiers in pharmacology · 2024
    Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Wenqiang TaoDepartment of Intensive Care Medicine, First Affiliated Hospital of Nanchang University, Nanchang, China.
Fen LiuDepartment of Intensive Care Medicine, First Affiliated Hospital of Nanchang University, Nanchang, China.
Jianguo ZhangDepartment of Infection, First Affiliated Hospital of Nanchang University, Nanchang, China.
Shangmiao FuDepartment of Intensive Care Medicine, First Affiliated Hospital of Nanchang University, Nanchang, China.
Hui ZhanDepartment of Intensive Care Medicine, First Affiliated Hospital of Nanchang University, Nanchang, China.
Kejian QianDepartment of Intensive Care Medicine, First Affiliated Hospital of Nanchang University, Nanchang, China.
First Affiliated Hospital of Nanchang University · CNNanchang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Renal ischemia-reperfusion (IR) is frequently observed in patients who are critically ill, yet there are no reliable or effective approaches for the treatment of this condition. Ferroptosis, a form of programmed cell death, is regulated by key genes such as glutathione peroxidase 4 (

Indexed as

acute kidney injuryferroptosisheme oxygenase-1ischemia-reperfusionmicroRNA

Identifiers

PMID35047556
PMCPMC8762253
OpenAlexW4206326856

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.